ArQule expects $48.7M from offering as it advances c-MET inhibitor tivantinib
This article was originally published in Scrip
The oncology biotech company ArQule has priced a public offering, and has also increased the offering, from a reported 6 million shares to 7.15 million shares. Shares are now priced at $7.30 each, a 2.1% discount to the share price at the close of 10 April. Net proceeds are expected to be about $48.7 million.